Elevated homocysteine levels area ssociated with an increased cardiovascular disease (CVD) risk,b ut the underlying mechanismi ss till unclear.High homocysteine might affectt he endothelium,and consequentlyleadtoimpairedhaemostasis. In a randomized placebo controlled triala mong2 76 oldera dults with plasma total homocysteine concentrations above 13 mM at screening, we investigatedthe effect of homocysteine lowering by folic acid supplementation(0.8 mg/day) for1year on markers of endothelialfunction(vonWillebrand factor), coagulation (tissuef actor,f actor VIIa, fragments 1+2), and fibrinolysis( fibrin Keywords Homocysteine, folic acid,haemostasis, homocysteine, intervention degradation products, tissue-type plasminogena ctivator), and inflammation (C-reactivep rotein).Despite a2 4% reduction in plasmah omocysteinec oncentration and four-foldi ncrease in serumfolate concentration in thefolicacid group compared to the placebo group,there was no clear change in anyofthe haemostasism arkers, nor CRP.Althoughh omocysteinei sa ssociated with vascular disease risk in the generalpopulation,marked loweringo fs lightlye levated homocysteine concentrations by one-yearfolicacid supplementationdoesnot influencehaemostasis markers. 
Introduction
Elevatedh omocysteine levels are associatedw ith an increased cardiovascular disease(CVD) risk (1) . However, homocysteine levels can be effectivelylowered by supplementation with folic acid (3) . Homozygosity for the 677C>T mutation in the gene encoding methylenetetrahydrofolate reductase (MTHFR), an enzyme involved in homocysteine remethylation, hasb een associatedw ith a1 6% increase in risk of coronaryh eartd isease (CHD) (4) . This finding supports the hypothesis that an impaired homocysteine or folate metabolism is causallyrelated to CHD, although the mechanism is still unclear.A nimal and in vitro studieshavesuggestedthat homocysteine might damage the endothelium, therebyinducing atherothrombosis by stimulation of procoagulant pathwaysand impairment of anti-coagulant and fibrinolytic pathways ( 5) . However, observationala nd intervention studies in humans have shown mixed results .
In this studyw einvestigated the effect of homocysteine reduction by folic acids upplementation for 1y ear on various markers of haemostasis includingv on Willebrand Factor (VWF), tissue factor (TF), factor VIIa (FVIIa),p rothrombin fragment 1+2 (F 1+2 ), fibrin degradation products(FbDP),tissuetype plasminogenactivator activity (tPA -activity) in volunteers aged . Theinflammation markerC-reactive protein (CRP) wasevaluatedbecauseithas been proposed thatelevatedhomocysteine levels contribute to low-grade inflammation (27) , and changes in haemostasis might be related to changes in inflammatorycondition (28) .
Materials andmethods

Subjects
This study is partofalarger placebo controlleddouble blind trial among819 older adults volunteers examining the effect of folic acidsupplementation for 3years on the progression of carotid artery intima-mediathickness. In this sub-trial we focused on the effect of 1-year folic acids upplementation on haemostasis markers in 276 subjectswho were randomized between Septem-ber and December 2000. Subjectsw ere recruitedf rom local blood banks and municipal registriesi nW ageningena nd surroundings.Subjects were eligibleiftheywere between 50 and 70 years old, had no thyroid or renal disease, did not use drugs that affect homocysteine or progression of intima-media thickness (i.e.hormone replacement or lipidlowering therapy), and didnot use B-vitamin supplements. Wo menwere postmenopausalorin caseofhysterectomy>55 years.Atscreening, plasma homocysteine valueshad to be between 13 and 26 µ M, and serumvitamin B 12 concentrations >200 pM. The study wasa pprovedb yt he medicalethicscommittee of the WageningenUniversity; written informedconsent wasobtained from all participants.
Design
During ascreening visit blood wastaken to determine homocysteine and serumv itamin B 12 concentrations. After a6 -week placebo run-in period,s ubjects were randomized to oral treatment with folic acid( 0.8 mg/d) or placebo in capsule-form (Swiss Caps Benelux,R oosendaal, The Netherlands). At baseline and after oney ear,b lood wasc ollected. Compliance was judged by pill-returnc ounts and ac alendar thatr egistered missedp ills, both of whichw ere returned everyt welvew eeks. All subjects fulfilledo ur compliancec riterion whichw as defined as >80% of capsules taken.
Bloodcollection and analysis
After thesubjecthad been seated for15minutes, fasting blood samples were drawn into evacuated vialsw ithoutm oving the needleinthe vein. Blood usedf or determination of serumv itamin B 12 ,f olate and lipids wasc ollectedi ns erum separator vials, whichwere placed in the dark and stored at roomtemperaturefor 30-60 min before centrifugation. Blood used for determination of plasma homocysteine concentration wascollectedin EDTAcontaining vials, for determination of FVIIA, VWF,TF, F 1+2 and CRPincitrate-containing vials, and fordetermination of tPAinStabilyte vials. Wherenecessary,vials were directlyput on ice until centrifugation. The plasma wasseparated fromblood cells within 30 minutesbycentrifugation at 2000 xgfor 20 min at the appropriate temperature. Samples were quicklyf rozen using dry-iceand stored at -80°C until analysis. Pre-and postintervention samples of aparticipant, except forfolate and vitamin B 12 ,were analyzed in the same runtominimizevariability. Folate and vitamin B 12 concentrations were measured with a commercial chemiluminescent immunoassaya nalyzer( Immulite 2000, Diagnostic Products Company,L os Angeles, USA). The intra-assayc oefficientso fv ariation (CV) of these assays were all <10%. Creatinine concentrations and lipid profile were determinedbyHitachi 747. Totalplasma homocysteine concentrations were measured by HPLC withf luorimetric detection (intra-and interassay CV 2% and 7%,respectively) (29) .Commercialkits were used to determine plasma concentrations of TF (Actichrome TF,American Diagnostica, Greenwich, USA), Factor VIIa (StaClot VIIa-rTF,S tago, Asnières, France),F 1+2 (Enzygnost, Dade-Behring, Marburg,G ermany), FbDP( Fibrinostika  FbDP, Organon Technika,B oxtel, TheN etherlands), and to measuretPA -activity (Chromalizet-Pa, Biopool, Umeå, Sweden). Home-made ELISAw ith polyclonala ntibodies was used for determination of VWFand high sensitive CRP concentration (Dako, Glastrup, Denmark). The intra-and interassay CVsw ere all< 10%, except forF VIIa (intra-assayC V<15%), and for TF (inter-assayCV<15%). Genomic DNAwas isolated from whole blood. The MTHFR 677C>T genotype wasd eterminedbyPCR and restriction enzyme digestion with HinFI, according to Frosst et al. (30) .All laboratorystaff wasblindedfor the treatment allocation.
Othermeasurements
As elf-reportedm edical historyw as attainedb yq uestionnaire and reviewedbyaresearch assistant. The questionnaire included questions on smoking, prevalent diseases,current drug use and familyhistoryofpremature vasculardisease(onset <60years in first degree family).Aparticipant wasconsideredtohaveprevalent vasculardiseaseifhehad been diagnosed with angina pectoris, myocardialinfarction, arrhythmia, stroke, or peripheral arterial diseaseorifhehad undergone balloon angioplasty,coronaryb ypass surgeryo ra ortic aneurysm surgery. Heighta nd weight wasmeasured to calculatebody mass index. Blood pressure wasmeasured using an automated meter(Dinamap Compact Pro, GeneralE lectric) in supine position. Thea verage of eight measurementsw as taken. Hypertension wasd efineda s systolic blood pressure ≥ 160 mmHg, diastolicb lood pressure ≥ 95 mmHg or use of antihypertensive medication. Hypercholesterolaemiawas definedastotal cholesterol <6.5 mM or high densitylipoprotein cholesterol <0.9 mM.
Statistics
Descriptivedataare shownasmeans ±SD, medians and interquartiler angeo rf requencies. Differences at baseline between the folic acidand placebo group were testedbystudent t tests or Pearson's chi-square tests, for continuous and categorical variablesr espectively. Skewed continuous data were natural log transformed beforet esting. Pearson's correlation coefficients were calculatedt oe xamine the relation betweenf olate and homocysteine concentrations on the one hand with markers of haemostasis and CRP on the other handinthe total population at baseline.
Baseline and 1-yearv alues,a nd changes of homocysteine, folate, haemostasis markers and CRP are presented as medians and interquartilerange. Persubject, treatment effect wascalculatedasthe percentage change relative to baseline values. Forall variables, the percentage changew as notn ormallyd istributed and we therefore used anatural logtransformation. Differences in (natural logt ransformed) baseline valuesa nd changes betweenthe twointervention groups were testedwith student t tests (a=0.05). Analysis of variance wasusedtoinvestigatew hether the MTHFR 677 C>Tp olymorphism influenced treatment effects.D ata-analysis wasp erformed with the Statistical Application Software forPC, version 6.12 (SAS institute Inc.,Cary, North Carolina,USA).
Results
The trial comprised 139 participants in the placebo group and 137 participants in the folic acid group (Table 1) . Va luesofconventional cardiovascularrisk factors, and vitamin B 6 and B 12 levels were in the normalrangeand not statisticallydifferent be-tween groups. Prevalenceofdiabetesmellitus and CVDoruse of CVD-relateddrugs did also not differbetween the twogroups. The MTHFR6 77TT genotype wasm ore prevalent and the CT genotype less prevalent in the folic acidgroupcompared with the placebo group (P<0.05).
At baseline, homocysteine and folate were notc orrelated with anyofthe haemostasis markers (datanot shown).Asshown in table 2, baseline concentrations of folate, vitamin B12, haemostasis markers and CRP were in the normalrangeand not different betweenb oth treatment groups. Baseline homocysteine concentration wass ignificantly higher in the folic acid group (Table 2) , whichmight be due to the higher prevalenceofthe TT genotype.
After 1-year supplementation, mean folate concentration wassignificantly increased by 319% (=36 nM) and meanhomocysteine concentration significantly decreasedb y2 4% (=3.1 mM) in the folic acid group, comparedwith the placebo group ( Table 2) . Folic acidsupplementation did not affect haemostasis markers, norCRP ( Table 2) .
Although subjects witht he MTHFR 677TT polymorphism had significantly higher baseline homocysteine concentrations, lowerf olate concentrations (data not shown) and exhibited a greater homocysteine reduction,the polymorphism did not appeart oi nfluence the effect of folic acid supplementation on markers of haemostasis or CRP (Table 3) .
Discussion
In this randomized placebo controlledtrial among middle-aged volunteers,folic acid supplementation for 1year didnot have an effect on haemostasis markers or CRP,despite aconsiderablereduction in homocysteine ( ≈ 24%) and alarge increase in serum folate ( ≈ 319%) concentrations. Although normal to marginally elevatedhomocysteine levels are associatedwith increased risk of vasculardisease, it is unlikelythat homocysteine acts by influencinghaemostasis in the general population.
To our knowledge,t his is the first largep lacebo-controlled intervention trialt hat examinedt he effect of homocysteinelowering at variousstagesofthe coagulation pathway,together with markers of endothelialfunction and inflammation performed in arepresentativesampleofolderadults without overtCVD. Although thes ubjects were recruitedf rom the general population, theyare believedtobeathigherrisk of CVD as theywere selected basedo nm oderately elevatedp lasma totalh omocysteine concentrations ( ≥ 13 µ M). Form ost of the measured markers there is considerablee videncet hat theya re positively associatedwith (31, 32) or even predict risk of CVD (10, (33) (34) (35) (36) (37) (38) .
Our hypothesis wasthat homocysteine impairs the endothelium suchthat coagulation is enhanced. Adverse effects on the endothelium should be reflectedb ya ni ncrease in VWF ( 39) . Homocysteine has beenshown to increase transcription and activity of TF from macrophages in the vesselw all (40) (41) (42) (43) , and therefore might stimulate the release of TF from the vesselwall. This would leadtoanincreased state of activation of the extrinsic coagulation cascade (increasing levels of FVIIa and F 1+2 )and subsequentlyr eactivefibrinolysis (increasing tPA-activity and FbDPc oncentrations). CRPw as evaluated, because elevated homocysteine levels maycontribute to low-grade inflammation (27) , and inflammation maylead to coagulation activation (28). Although we expected that homocysteine lowering by folic acid supplementation would decrease the concentration or activity of VWF, haemostasis markers, and CRP,n oe ffect of folic acid supplementation on anyo ft he markers waso bserved. In addi- tion, homocysteine concentration wasnot correlated with anyof the haemostasis markers at baseline. Our results are notlikelyexplained by poor quality of plasma samples used for determination of haemostasis markers since we followedastrictprotocolfor sampling and handling of the blood. Furthermore,t he CVs of haemostasis markers were all below 15%. However, three possible explanations areconceivablefor our results.
First,given the uncertainty regarding the mechanism underlying increased atherothrombotic risk in association with elevated homocysteine levels, it is possible thatrelevant haemostatic mechanisms aren ot being monitoredb yt he assays chosenf or analysis. However, twootherplacebo-controlledtrials studying the effect of B-vitamin supplementation on haemostasis in healthyv olunteersd id not find anyc lear effect,a lthough also otherm arkers thano urs were measured in these trials (21,2 2, 26) .
Second,results from a6-month trialonin-stent restenosis by Lange et al. (47) suggest that positive effectsoffolic acid treatment maybegreater in thosewith baseline homocysteine levels ≥ 15 µ M. The averagehomocysteine concentrations of our participants might have beentoo lowtohaveadverselyaffected haemostasis. At screening,weselected peoplewith ahomocysteine ≥ 13 mM. Howeveratbaseline,only46% of the subjects still had homocysteine values ≥ 13 mM, probablydue to regression to the mean. This might have lowered the powerofour trial. In anonplacebo controlled trial, Undase ta l. (48)s upplemented1 7 healthysubjects with fasting homocysteine levels >16 µ Mwith a high dose of B-vitamins for 8weeks and foundasignificant reduction of F 1+2 and thrombin-antithrombin. However, we did not find anyd ifference in effect on haemostasis or CRP when we stratified the analyses according to baseline homocysteine values (datanot shown).Inaddition, we did not observe anydifference in effect between MTHFR 677C>Tgenotypes, whichisin line with the results from twootherstudies (21, 24) .
In threes tudies, acuteh yperhomocysteinemia inducedb y methionine loading significantly increased levels of VWF, F 1+2 , D-dimer,t PA and PA I ( 7, 49, 50) . However, it could be questionedwhetherthese acute large effects on homocysteine could be comparedwith chronically elevatedfasting homocysteine levels. Some studiesi nh omocystinuria patients suggest that chronicallyh igh homocysteine levels are associatedw ith increased haemostatic dysbalance (51) .
Third,inour middleaged population, levels of haemostasis factorswere relativelylow compared to vascularpatients (6, 32, 35, 45) , and possibly could not be reduced anyfurther.Evenin the highestt ertile of haemostasis markers or CRP,n oe ffect of folic acidsupplementation could be observed(data not shown).
Our results do not excludep ossible effects in patients with compromised endothelial function. Several studiesinvestigated the effect of high dose folic acidsupplementation for aperiod of three monthst oo ne year on haemostasis in vascularp atients. Oneofthese studies showedasignificant reduction in VWF (18) . Twos tudiesd id not find an effect on the same markers as we measured in our study ( 19, 20) , whereas twoo thers tudieso bserveds ignificant effectso ns ome other haemostasis markers (23, 24) . However, it should be notedthat most of these studies did not include aplacebo group and sample sizeswere generally small. Moreover, results of aplacebo-controlledtrial in 285 patients with previous transient ischaemic attack or strokerecently showedthat homocysteine-lowering didnot significantly reduce blood concentrations of biomarkersofinflammation, endothelial dysfunction, or hypercoagulability (52) .
In conclusion, our findings indicate that it is unlikelyt hat slightlyelevatedhomocysteine levels increase the risk of afirst CVD event throughe ffectso nh aemostasis. Morer andomized trials are needed to evaluate whether homocysteine lowering would have ab eneficiale ffect on haemostasis amongs ubjects with documented clinicalmanifestation of CVD. the Practisefor creating the database; the laboratorystaffofthe Division of Human Nutrition of Wageningen University forthe homocysteine analyses and the MTHFR 677C>T genotyping; Piet Meijer and the laboratorystaff of the Gaubius LaboratoryofTNO Preventionand Health formeasuring the haemostasis markersand CRP;the laboratorystaffofthe University Medical CentreNijmegen forfolate, vitamin B 12 and lipidprofile analyses;and the volunteersfor their enthusiastic participation. 
